focus -WSS

focus

author：knowledge 2025-09-06 02:15:35 - browse：814

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Humana sues Biden admin over Medicare Advantage audit rule

leisure time

WSS

A rare thyroid diagnosis led to unexpected, all

How to protect patients from sexual assault

Stem cell treatment guidelines are released by FDA

Snackable artificial intelligence, expert AI, and the pharma industry

What American doctors can learn from their Israeli counterparts

'Make People Better': The CRISPR babies story you probably don't know

focus

focus

knowledge

Supreme Court strikes down use of affirmative action

Medical bills so high, Medicare adding extra digits to claim forms

BioMarin wins approval for gene therapy to treat hemophilia A

Snackable artificial intelligence, expert AI, and the pharma industry

Continuity nursing helped my family in our darkest PICU moments

What American doctors can learn from their Israeli counterparts

Peter Hotez and the public health issue of online harassment

Snackable artificial intelligence, expert AI, and the pharma industry

Apple is now the first public company to be valued at $3 trillion

Getting Alzheimer's drug Leqembi to patients can be a challenge

focus

Medicaid rebukes states for mistakenly disenrolling children

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Amazon on where the company's health care bets are headed next

NIH nominee Bertagnolli will get October confirmation hearing

MultiPlan and major insurers sued for alleged medical price

NIH nominee Bertagnolli will get October confirmation hearing

leisure time

entertainment

leisure time

explore